Bloomberg: "Novartis AG (NOVN) won “breakthrough” status from - TopicsExpress



          

Bloomberg: "Novartis AG (NOVN) won “breakthrough” status from U.S. regulators for an experimental drug to treat acute heart failure, raising the prospect of faster approval. .../... Serelaxin, a man-made version of a hormone found in pregnant women, reduced death rates by 37 percent in patients with acute heart failure six months after treatment, according to clinical trial results presented last year."
Posted on: Sat, 22 Jun 2013 03:21:33 +0000

Trending Topics



Recently Viewed Topics




© 2015